赛马鲁肽
医学
磷酸西他列汀
安慰剂
利拉鲁肽
不利影响
恩帕吉菲
杜拉鲁肽
内科学
科克伦图书馆
荟萃分析
雷公藤
2型糖尿病
磷酸西他列汀
随机对照试验
糖尿病
内分泌学
替代医学
病理
作者
Mohamed Sayed Zaazouee,Aboalmagd Hamdallah,Sara Kamel Helmy,Elfatih A. Hasabo,Ahmed Kamal Sayed,Mohamed Ibrahim Gbreel,Aya Abd Elmegeed,Hala Aladwan,Alaa Ahmed Elshanbary,Walid Abdel-Aziz,Israa Mohamed Elshahawy,Shehab Rabie,Sherouk Elkady,Ahmed Said Ali,Khaled Mohamed Ragab,Anas Zakarya Nourelden
标识
DOI:10.1016/j.dsx.2022.102511
摘要
To assess the safety and efficacy of semaglutide compared with placebo and other anti-hyperglycaemic agents in type 2 diabetes (T2DM).We searched PubMed, Scopus, Web of Science, and Cochrane library for relevant randomized controlled trials (RCTs). A network meta-analysis was conducted to compare different doses, durations, and interventions in T2DM. We presented results as mean difference (MD) or relative risk (RR) and 95% confidence interval (CI).Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo. Tirzepatide showed the highest efficacy, however, it was comparable to semaglutide. SC semaglutide 1 mg once-weekly showed higher reduction in HbA1c (MD = -1.72, 95% CI [-2.32; -1.12]), and fasting blood glucose (MD = -1.93, 95% CI [-2.81; -1.04]) versus placebo at 30 weeks and other timepoints. Adverse events (ADs) were comparable to placebo with oral and SC semaglutide, oral sitagliptin, SC liraglutide, and oral empagliflozin at most timepoints. However, SC semaglutide 0.8 mg and tirzepatide 10 mg groups had the highest gastrointestinal adverse events.Tirzepatide, oral and SC semaglutide has a favourable efficacy in treating T2DM. The adverse events were comparable to placebo; however, gastrointestinal adverse events were highly recorded in tirzepatide, oral and SC semaglutide groups.
科研通智能强力驱动
Strongly Powered by AbleSci AI